If a pregnant woman begins opioid agonist therapy, what complication is likely to be reduced?

Engaging in opioid agonist therapy during pregnancy is associated with a reduction in the likelihood of preterm labor and delivery. Opioid agonist therapy, such as the use of methadone or buprenorphine, helps stabilize the mother’s opioid dependence and reduces the risk of withdrawal symptoms that can lead to stress and complications during pregnancy. This stabilization allows for a healthier pregnancy trajectory, which is crucial in minimizing the chances of preterm birth.

In contrast, congenital anomalies, fetal macrosomia, and placenta accreta spectrum are complications that may not exhibit the same degree of reduction with the implementation of opioid agonist therapy. While adequate prenatal care, including appropriate opioid therapy, can support better outcomes, preterm labor is particularly impacted by the stability provided through opioid agonist treatment, making it a relevant focus in managing pregnant women with opioid dependence.